Product Description
Mechanisms of Action: CD4 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biotest AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Asthma, Allergic|Psoriasis|Environmental Hypersensitivity|Inflammation|Dust mite Hypersensitivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Tregulaire | P2 |
Completed |
Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity |
2022-01-12 |
|
| Tregulaire | P2 |
Completed |
Dust mite Hypersensitivity|Environmental Hypersensitivity|Asthma, Allergic|Inflammation |
2022-01-12 |
35% |
| T cell REgulating Arthritis Trial 2b (TREAT 2b) | P2 |
Terminated |
Arthritis, Rheumatoid |
2016-11-29 |
|
| 986 | P2 |
Terminated |
Arthritis, Rheumatoid |
2015-07-01 |